Psyence Biomedical (PBM) is a potential multi-bagger due to a historic regulatory catalyst in psychedelic therapies, despite current financial challenges.
Source Post
Psyence Biomedical: Ibogaine Gov Order Sparks PBM Multi-Bagger Rally! | PBM Stock Analysis
Apr 19, 2026
This podcast episode discusses Psyence Biomedical (PBM), a clinical-stage biopharma company focused on addiction treatments derived from naturally occurring compounds. Despite a significant stock drop and zero commercial revenue, the company is positioned to benefit from a potential US government policy shift regarding psychedelic therapies. The discussion covers the company's financial situation, including its cash burn and liquidity, highlighting the high costs associated with clinical trials and intellectual property acquisition in the sector.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.